Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial

  1. Cools, F.
  2. Virdone, S.
  3. Sawhney, J.
  4. Lopes, R.D.
  5. Jacobson, B.
  6. Arcelus, J.I.
  7. Hobbs, F.D.R.
  8. Gibbs, H.
  9. Himmelreich, J.C.L.
  10. MacCallum, P.
  11. Schellong, S.
  12. Haas, S.
  13. Turpie, A.G.G.
  14. Ageno, W.
  15. Rocha, A.T.
  16. Kayani, G.
  17. Pieper, K.
  18. Kakkar, A.K.
  19. Avhad, A.
  20. Antunes, M.
  21. Thereza Rocha, A.
  22. Gonzales Lama, J.
  23. Abyankar, A.
  24. Kormann, A.P.M.
  25. Van Zyl, L.
  26. Kaul, U.
  27. Adams, F.
  28. Aloysius, I.
  29. Capehorn, M.
  30. Kumar, P.
  31. Mahajan, R.
  32. Erakutsi egile guztiak +
Aldizkaria:
The Lancet Haematology

ISSN: 2352-3026

Argitalpen urtea: 2022

Alea: 9

Zenbakia: 8

Orrialdeak: e594-e604

Mota: Artikulua

DOI: 10.1016/S2352-3026(22)00173-9 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus